KR102603469B1 - COVID-19 Virucidal composition comprising PURITON and uses thereof - Google Patents
COVID-19 Virucidal composition comprising PURITON and uses thereof Download PDFInfo
- Publication number
- KR102603469B1 KR102603469B1 KR1020200169727A KR20200169727A KR102603469B1 KR 102603469 B1 KR102603469 B1 KR 102603469B1 KR 1020200169727 A KR1020200169727 A KR 1020200169727A KR 20200169727 A KR20200169727 A KR 20200169727A KR 102603469 B1 KR102603469 B1 KR 102603469B1
- Authority
- KR
- South Korea
- Prior art keywords
- weight
- virus
- present
- composition
- killing
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 64
- 208000025721 COVID-19 Diseases 0.000 title claims description 10
- 230000003253 viricidal effect Effects 0.000 title description 5
- 241000711573 Coronaviridae Species 0.000 claims description 16
- 241001678559 COVID-19 virus Species 0.000 claims description 9
- 229910052618 mica group Inorganic materials 0.000 claims description 6
- 229910052901 montmorillonite Inorganic materials 0.000 claims description 6
- 229910021536 Zeolite Inorganic materials 0.000 claims description 5
- 229910052836 andradite Inorganic materials 0.000 claims description 5
- GUJOJGAPFQRJSV-UHFFFAOYSA-N dialuminum;dioxosilane;oxygen(2-);hydrate Chemical compound O.[O-2].[O-2].[O-2].[Al+3].[Al+3].O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O GUJOJGAPFQRJSV-UHFFFAOYSA-N 0.000 claims description 5
- HNPSIPDUKPIQMN-UHFFFAOYSA-N dioxosilane;oxo(oxoalumanyloxy)alumane Chemical compound O=[Si]=O.O=[Al]O[Al]=O HNPSIPDUKPIQMN-UHFFFAOYSA-N 0.000 claims description 5
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 claims description 5
- 239000010445 mica Substances 0.000 claims description 5
- 229910052625 palygorskite Inorganic materials 0.000 claims description 5
- 239000010457 zeolite Substances 0.000 claims description 5
- WYTGDNHDOZPMIW-RCBQFDQVSA-N alstonine Natural products C1=CC2=C3C=CC=CC3=NC2=C2N1C[C@H]1[C@H](C)OC=C(C(=O)OC)[C@H]1C2 WYTGDNHDOZPMIW-RCBQFDQVSA-N 0.000 claims description 4
- 229960000892 attapulgite Drugs 0.000 claims description 4
- 229910052626 biotite Inorganic materials 0.000 claims description 4
- 229910001593 boehmite Inorganic materials 0.000 claims description 4
- YGANSGVIUGARFR-UHFFFAOYSA-N dipotassium dioxosilane oxo(oxoalumanyloxy)alumane oxygen(2-) Chemical compound [O--].[K+].[K+].O=[Si]=O.O=[Al]O[Al]=O YGANSGVIUGARFR-UHFFFAOYSA-N 0.000 claims description 4
- 229910052855 humite Inorganic materials 0.000 claims description 4
- FAHBNUUHRFUEAI-UHFFFAOYSA-M hydroxidooxidoaluminium Chemical compound O[Al]=O FAHBNUUHRFUEAI-UHFFFAOYSA-M 0.000 claims description 4
- 229910052622 kaolinite Inorganic materials 0.000 claims description 4
- 229910052629 lepidolite Inorganic materials 0.000 claims description 4
- 239000001095 magnesium carbonate Substances 0.000 claims description 4
- 229910000021 magnesium carbonate Inorganic materials 0.000 claims description 4
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 claims description 4
- 235000014380 magnesium carbonate Nutrition 0.000 claims description 4
- 229910052627 muscovite Inorganic materials 0.000 claims description 4
- 229910052664 nepheline Inorganic materials 0.000 claims description 4
- 239000010434 nepheline Substances 0.000 claims description 4
- 229910052628 phlogopite Inorganic materials 0.000 claims description 4
- 229910052613 tourmaline Inorganic materials 0.000 claims description 4
- 239000011032 tourmaline Substances 0.000 claims description 4
- 229940070527 tourmaline Drugs 0.000 claims description 4
- 229910052902 vermiculite Inorganic materials 0.000 claims description 4
- 239000010455 vermiculite Substances 0.000 claims description 4
- 235000019354 vermiculite Nutrition 0.000 claims description 4
- 229910000514 dolomite Inorganic materials 0.000 claims description 3
- 239000010459 dolomite Substances 0.000 claims description 3
- 239000010433 feldspar Substances 0.000 claims description 3
- 229910001679 gibbsite Inorganic materials 0.000 claims description 3
- 229910052631 glauconite Inorganic materials 0.000 claims description 3
- 229910052900 illite Inorganic materials 0.000 claims description 3
- VGIBGUSAECPPNB-UHFFFAOYSA-L nonaaluminum;magnesium;tripotassium;1,3-dioxido-2,4,5-trioxa-1,3-disilabicyclo[1.1.1]pentane;iron(2+);oxygen(2-);fluoride;hydroxide Chemical compound [OH-].[O-2].[O-2].[O-2].[O-2].[O-2].[F-].[Mg+2].[Al+3].[Al+3].[Al+3].[Al+3].[Al+3].[Al+3].[Al+3].[Al+3].[Al+3].[K+].[K+].[K+].[Fe+2].O1[Si]2([O-])O[Si]1([O-])O2.O1[Si]2([O-])O[Si]1([O-])O2.O1[Si]2([O-])O[Si]1([O-])O2.O1[Si]2([O-])O[Si]1([O-])O2.O1[Si]2([O-])O[Si]1([O-])O2.O1[Si]2([O-])O[Si]1([O-])O2.O1[Si]2([O-])O[Si]1([O-])O2 VGIBGUSAECPPNB-UHFFFAOYSA-L 0.000 claims description 3
- XAAHAAMILDNBPS-UHFFFAOYSA-L calcium hydrogenphosphate dihydrate Chemical compound O.O.[Ca+2].OP([O-])([O-])=O XAAHAAMILDNBPS-UHFFFAOYSA-L 0.000 claims description 2
- 241000700605 Viruses Species 0.000 abstract description 73
- 229910052500 inorganic mineral Inorganic materials 0.000 abstract description 33
- 239000011707 mineral Substances 0.000 abstract description 33
- 230000002147 killing effect Effects 0.000 abstract description 24
- 150000002500 ions Chemical class 0.000 abstract description 13
- 239000004480 active ingredient Substances 0.000 abstract description 11
- 239000002537 cosmetic Substances 0.000 abstract description 8
- 239000003814 drug Substances 0.000 abstract description 7
- 229940079593 drug Drugs 0.000 abstract description 5
- 239000000645 desinfectant Substances 0.000 abstract description 3
- 239000004753 textile Substances 0.000 abstract description 3
- 210000000170 cell membrane Anatomy 0.000 abstract description 2
- 210000003855 cell nucleus Anatomy 0.000 abstract description 2
- 230000002401 inhibitory effect Effects 0.000 abstract description 2
- 235000010755 mineral Nutrition 0.000 description 32
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 19
- 238000000034 method Methods 0.000 description 18
- 230000008569 process Effects 0.000 description 15
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 14
- 239000004615 ingredient Substances 0.000 description 12
- -1 Sylvanite Inorganic materials 0.000 description 11
- 238000009472 formulation Methods 0.000 description 11
- 208000015181 infectious disease Diseases 0.000 description 11
- 229910052782 aluminium Inorganic materials 0.000 description 10
- 230000000694 effects Effects 0.000 description 10
- 239000008194 pharmaceutical composition Substances 0.000 description 10
- 239000000843 powder Substances 0.000 description 10
- 230000009467 reduction Effects 0.000 description 10
- 239000011777 magnesium Substances 0.000 description 8
- 239000000243 solution Substances 0.000 description 7
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- 208000036142 Viral infection Diseases 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 6
- 239000002734 clay mineral Substances 0.000 description 6
- 239000006071 cream Substances 0.000 description 6
- 230000000120 cytopathologic effect Effects 0.000 description 6
- 238000010790 dilution Methods 0.000 description 6
- 239000012895 dilution Substances 0.000 description 6
- 229910052742 iron Inorganic materials 0.000 description 6
- 229910052749 magnesium Inorganic materials 0.000 description 6
- 230000009385 viral infection Effects 0.000 description 6
- 230000003612 virological effect Effects 0.000 description 6
- 239000000440 bentonite Substances 0.000 description 5
- 229910000278 bentonite Inorganic materials 0.000 description 5
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 5
- 235000014113 dietary fatty acids Nutrition 0.000 description 5
- 235000019441 ethanol Nutrition 0.000 description 5
- 239000000194 fatty acid Substances 0.000 description 5
- 229930195729 fatty acid Natural products 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 239000002609 medium Substances 0.000 description 5
- 238000006386 neutralization reaction Methods 0.000 description 5
- 229910052710 silicon Inorganic materials 0.000 description 5
- 239000007921 spray Substances 0.000 description 5
- 230000001988 toxicity Effects 0.000 description 5
- 231100000419 toxicity Toxicity 0.000 description 5
- 238000011282 treatment Methods 0.000 description 5
- 241000709687 Coxsackievirus Species 0.000 description 4
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 4
- 229930182566 Gentamicin Natural products 0.000 description 4
- 241000315672 SARS coronavirus Species 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- 239000001913 cellulose Substances 0.000 description 4
- 235000010980 cellulose Nutrition 0.000 description 4
- 229920002678 cellulose Polymers 0.000 description 4
- 241001493065 dsRNA viruses Species 0.000 description 4
- 239000000839 emulsion Substances 0.000 description 4
- 239000000499 gel Substances 0.000 description 4
- 229960002518 gentamicin Drugs 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 239000006210 lotion Substances 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 239000013642 negative control Substances 0.000 description 4
- 239000002245 particle Substances 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 239000011573 trace mineral Substances 0.000 description 4
- 235000013619 trace mineral Nutrition 0.000 description 4
- 229910000789 Aluminium-silicon alloy Inorganic materials 0.000 description 3
- 241001466953 Echovirus Species 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- 239000002202 Polyethylene glycol Substances 0.000 description 3
- 231100000645 Reed–Muench method Toxicity 0.000 description 3
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 238000004113 cell culture Methods 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 239000003937 drug carrier Substances 0.000 description 3
- 239000010419 fine particle Substances 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 238000000227 grinding Methods 0.000 description 3
- 230000002458 infectious effect Effects 0.000 description 3
- 230000035800 maturation Effects 0.000 description 3
- 239000002105 nanoparticle Substances 0.000 description 3
- 235000016709 nutrition Nutrition 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- 239000002994 raw material Substances 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 230000001954 sterilising effect Effects 0.000 description 3
- 238000004659 sterilization and disinfection Methods 0.000 description 3
- 239000000454 talc Substances 0.000 description 3
- 229910052623 talc Inorganic materials 0.000 description 3
- 235000012222 talc Nutrition 0.000 description 3
- 229960005486 vaccine Drugs 0.000 description 3
- 235000015112 vegetable and seed oil Nutrition 0.000 description 3
- 239000008158 vegetable oil Substances 0.000 description 3
- DNIAPMSPPWPWGF-GSVOUGTGSA-N (R)-(-)-Propylene glycol Chemical compound C[C@@H](O)CO DNIAPMSPPWPWGF-GSVOUGTGSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerol Natural products OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 229920000084 Gum arabic Polymers 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 244000309467 Human Coronavirus Species 0.000 description 2
- 241000701806 Human papillomavirus Species 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 235000019738 Limestone Nutrition 0.000 description 2
- 241000127282 Middle East respiratory syndrome-related coronavirus Species 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- ATUOYWHBWRKTHZ-UHFFFAOYSA-N Propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 description 2
- 229910004298 SiO 2 Inorganic materials 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 2
- 239000000205 acacia gum Substances 0.000 description 2
- 235000010489 acacia gum Nutrition 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 229910001583 allophane Inorganic materials 0.000 description 2
- 230000000840 anti-viral effect Effects 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- SESFRYSPDFLNCH-UHFFFAOYSA-N benzyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OCC1=CC=CC=C1 SESFRYSPDFLNCH-UHFFFAOYSA-N 0.000 description 2
- 229910052599 brucite Inorganic materials 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 239000000378 calcium silicate Substances 0.000 description 2
- 229910052918 calcium silicate Inorganic materials 0.000 description 2
- 235000012241 calcium silicate Nutrition 0.000 description 2
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 229910002091 carbon monoxide Inorganic materials 0.000 description 2
- 239000003599 detergent Substances 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 239000006028 limestone Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 230000003472 neutralizing effect Effects 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 229910052652 orthoclase Inorganic materials 0.000 description 2
- 239000006072 paste Substances 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000000241 respiratory effect Effects 0.000 description 2
- 208000023504 respiratory system disease Diseases 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 235000010356 sorbitol Nutrition 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 238000002255 vaccination Methods 0.000 description 2
- 230000001018 virulence Effects 0.000 description 2
- 230000005727 virus proliferation Effects 0.000 description 2
- 239000001993 wax Substances 0.000 description 2
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- 229910019487 (Mg, Al)2Si4O10 Inorganic materials 0.000 description 1
- WNWHHMBRJJOGFJ-UHFFFAOYSA-N 16-methylheptadecan-1-ol Chemical class CC(C)CCCCCCCCCCCCCCCO WNWHHMBRJJOGFJ-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 208000034579 Acute haemorrhagic conjunctivitis Diseases 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 229910018072 Al 2 O 3 Inorganic materials 0.000 description 1
- 229910018626 Al(OH) Inorganic materials 0.000 description 1
- 229910017121 AlSiO Inorganic materials 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 229920000856 Amylose Polymers 0.000 description 1
- 208000006740 Aseptic Meningitis Diseases 0.000 description 1
- 208000031504 Asymptomatic Infections Diseases 0.000 description 1
- 229910015369 AuTe Inorganic materials 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 208000002177 Cataract Diseases 0.000 description 1
- 108010001857 Cell Surface Receptors Proteins 0.000 description 1
- 206010008342 Cervix carcinoma Diseases 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 208000003556 Dry Eye Syndromes Diseases 0.000 description 1
- 206010013774 Dry eye Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- 201000011001 Ebola Hemorrhagic Fever Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 241000709661 Enterovirus Species 0.000 description 1
- 241000991587 Enterovirus C Species 0.000 description 1
- 206010014978 Epidemic pleurodynia Diseases 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 208000010412 Glaucoma Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 208000020061 Hand, Foot and Mouth Disease Diseases 0.000 description 1
- 208000025713 Hand-foot-and-mouth disease Diseases 0.000 description 1
- 201000006219 Herpangina Diseases 0.000 description 1
- 241000709716 Human enterovirus 70 Species 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 239000004166 Lanolin Substances 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 206010027201 Meningitis aseptic Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 229910019440 Mg(OH) Inorganic materials 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 208000000474 Poliomyelitis Diseases 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 208000036071 Rhinorrhea Diseases 0.000 description 1
- 206010039101 Rhinorrhoea Diseases 0.000 description 1
- 241000702670 Rotavirus Species 0.000 description 1
- 206010067470 Rotavirus infection Diseases 0.000 description 1
- 241000710799 Rubella virus Species 0.000 description 1
- 201000003176 Severe Acute Respiratory Syndrome Diseases 0.000 description 1
- 229910004283 SiO 4 Inorganic materials 0.000 description 1
- 240000006394 Sorghum bicolor Species 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- ULUAUXLGCMPNKK-UHFFFAOYSA-N Sulfobutanedioic acid Chemical compound OC(=O)CC(C(O)=O)S(O)(=O)=O ULUAUXLGCMPNKK-UHFFFAOYSA-N 0.000 description 1
- 229910010413 TiO 2 Inorganic materials 0.000 description 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
- 206010046914 Vaginal infection Diseases 0.000 description 1
- 201000008100 Vaginitis Diseases 0.000 description 1
- 208000020329 Zika virus infectious disease Diseases 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- DLHONNLASJQAHX-UHFFFAOYSA-N aluminum;potassium;oxygen(2-);silicon(4+) Chemical compound [O-2].[O-2].[O-2].[O-2].[O-2].[O-2].[O-2].[O-2].[Al+3].[Si+4].[Si+4].[Si+4].[K+] DLHONNLASJQAHX-UHFFFAOYSA-N 0.000 description 1
- 239000010775 animal oil Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 229960002903 benzyl benzoate Drugs 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 239000003462 bioceramic Substances 0.000 description 1
- 239000003124 biologic agent Substances 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 239000001273 butane Substances 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 229960001714 calcium phosphate Drugs 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 229960003340 calcium silicate Drugs 0.000 description 1
- HHSPVTKDOHQBKF-UHFFFAOYSA-J calcium;magnesium;dicarbonate Chemical compound [Mg+2].[Ca+2].[O-]C([O-])=O.[O-]C([O-])=O HHSPVTKDOHQBKF-UHFFFAOYSA-J 0.000 description 1
- 210000000234 capsid Anatomy 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 201000010881 cervical cancer Diseases 0.000 description 1
- 150000005827 chlorofluoro hydrocarbons Chemical class 0.000 description 1
- 229910052804 chromium Inorganic materials 0.000 description 1
- 239000004927 clay Substances 0.000 description 1
- 230000003749 cleanliness Effects 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000003240 coconut oil Substances 0.000 description 1
- 235000019864 coconut oil Nutrition 0.000 description 1
- 239000011365 complex material Substances 0.000 description 1
- 239000013068 control sample Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 239000002385 cottonseed oil Substances 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 201000003146 cystitis Diseases 0.000 description 1
- 230000010460 detection of virus Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 239000000686 essence Substances 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N ethylene glycol Natural products OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 208000030533 eye disease Diseases 0.000 description 1
- 239000003889 eye drop Substances 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 150000002191 fatty alcohols Chemical class 0.000 description 1
- 238000010304 firing Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 229940014259 gelatin Drugs 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 229910001385 heavy metal Inorganic materials 0.000 description 1
- 208000014617 hemorrhoid Diseases 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- MTNDZQHUAFNZQY-UHFFFAOYSA-N imidazoline Chemical class C1CN=CN1 MTNDZQHUAFNZQY-UHFFFAOYSA-N 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 235000019388 lanolin Nutrition 0.000 description 1
- 229940039717 lanolin Drugs 0.000 description 1
- 229910052746 lanthanum Inorganic materials 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- PALNZFJYSCMLBK-UHFFFAOYSA-K magnesium;potassium;trichloride;hexahydrate Chemical compound O.O.O.O.O.O.[Mg+2].[Cl-].[Cl-].[Cl-].[K+] PALNZFJYSCMLBK-UHFFFAOYSA-K 0.000 description 1
- 239000002075 main ingredient Substances 0.000 description 1
- 229910052748 manganese Inorganic materials 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 230000010198 maturation time Effects 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 102000006240 membrane receptors Human genes 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 239000013081 microcrystal Substances 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- CQDGTJPVBWZJAZ-UHFFFAOYSA-N monoethyl carbonate Chemical compound CCOC(O)=O CQDGTJPVBWZJAZ-UHFFFAOYSA-N 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- IJDNQMDRQITEOD-UHFFFAOYSA-N n-butane Chemical compound CCCC IJDNQMDRQITEOD-UHFFFAOYSA-N 0.000 description 1
- OFBQJSOFQDEBGM-UHFFFAOYSA-N n-pentane Natural products CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 1
- 239000005445 natural material Substances 0.000 description 1
- 231100001083 no cytotoxicity Toxicity 0.000 description 1
- 231100000065 noncytotoxic Toxicity 0.000 description 1
- 230000002020 noncytotoxic effect Effects 0.000 description 1
- 239000000820 nonprescription drug Substances 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 238000001543 one-way ANOVA Methods 0.000 description 1
- 229910000259 oneillite Inorganic materials 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 238000010149 post-hoc-test Methods 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 239000001294 propane Substances 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 201000005404 rubella Diseases 0.000 description 1
- 229910052701 rubidium Inorganic materials 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 229940071089 sarcosinate Drugs 0.000 description 1
- FSYKKLYZXJSNPZ-UHFFFAOYSA-N sarcosine Chemical compound C[NH2+]CC([O-])=O FSYKKLYZXJSNPZ-UHFFFAOYSA-N 0.000 description 1
- 239000000344 soap Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 235000013322 soy milk Nutrition 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 229940104261 taurate Drugs 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 229910052719 titanium Inorganic materials 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 229910052720 vanadium Inorganic materials 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 239000011787 zinc oxide Substances 0.000 description 1
- 229910052726 zirconium Inorganic materials 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N59/00—Biocides, pest repellants or attractants, or plant growth regulators containing elements or inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- C—CHEMISTRY; METALLURGY
- C11—ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
- C11D—DETERGENT COMPOSITIONS; USE OF SINGLE SUBSTANCES AS DETERGENTS; SOAP OR SOAP-MAKING; RESIN SOAPS; RECOVERY OF GLYCEROL
- C11D3/00—Other compounding ingredients of detergent compositions covered in group C11D1/00
- C11D3/02—Inorganic compounds ; Elemental compounds
- C11D3/12—Water-insoluble compounds
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Inorganic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Wood Science & Technology (AREA)
- Virology (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Dentistry (AREA)
- Plant Pathology (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Birds (AREA)
- Pest Control & Pesticides (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Communicable Diseases (AREA)
- Agronomy & Crop Science (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Environmental Sciences (AREA)
- Dermatology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
본 발명은 미네랄 이온 혼합물을 유효성분으로 포함하는 살바이러스 조성물에 관한 것으로서, 상기 조성물은 바이러스의 세포막 및 핵을 분해시키며 단일가닥 RNA를 절단하여 바이러스 증식 억제 및 살바이러스 효과가 매우 효과적이므로, 다양한 제품, 예를 들어, 의약품, 화장품, 섬유, 생활용품, 주방용품, 및 소독제 등에 유용하게 사용 가능하다.The present invention relates to a virus-killing composition containing a mixture of mineral ions as an active ingredient. The composition decomposes the cell membrane and nucleus of the virus and cleaves single-stranded RNA, so it is very effective in inhibiting virus growth and killing viruses, so it can be used in a variety of products. , For example, it can be usefully used in medicines, cosmetics, textiles, household goods, kitchenware, and disinfectants.
Description
본 발명은 미네랄 이온 혼합물을 유효성분으로 포함하는 살바이러스 조성물 및 바이러스 감염의 치료, 멸균, 및 소독을 위한 이의 용도에 관한 것이다.The present invention relates to a virus killing composition comprising a mineral ion mixture as an active ingredient and its use for treatment, sterilization, and disinfection of viral infections.
바이러스는 지구에서 가장 풍부한 생물학적 물질이고, 동물, 식물, 세균 및 진균을 포함하는 모든 유형의 세포 생명체를 감염시킬 수 있다. 바이러스 감염은 해마다 수백만 명의 사람들을 사망시키고 건강 관리 비용에 상당히 기여한다. 바이러스가 사회에 미칠 수 있는 부정적 영향은 식품, 작물 및 가축의 바이러스 감염부터 바이러스 감염, 예컨대, HIV, 에볼라(Ebola) 또는 지카(Zika)가 인간에 미치는 심각한 건강 영향까지 상당하다. 일부 바이러스 감염은 암과도 연관되어 있다(예컨대, 여성에서 네 번째로 가장 흔한 암인 자궁경부암과 연관되어 있는 인간 유두종바이러스(HPV)).Viruses are the most abundant biological agents on Earth and can infect all types of cellular life, including animals, plants, bacteria, and fungi. Viral infections kill millions of people each year and contribute significantly to health care costs. The negative impacts that viruses can have on society are significant, from viral infections of food, crops and livestock to the serious health impacts of viral infections such as HIV, Ebola or Zika on humans. Some viral infections have also been linked to cancer (e.g., human papillomavirus (HPV), which is associated with cervical cancer, the fourth most common cancer in women).
최근에는 2019년 12월 발생한 신종 감염증의 원인 바이러스로 신종코로나바이러스(COVID-19, SARS-CoV-2)가 사회적 문제로 되고 있다. 상기 신종코로나바이러스는 인체 감염 7개 코로나바이러스 중 하나로 감염자의 비말 (침방울)이 호흡기나 눈·코·입의 점막으로 침투될 때 전염되는 것으로 보고되었다. 감염되면 약 2~14일(추 정)의 잠복기를 거친 뒤 발열 및 기침이나 호흡곤란 등 호흡기 증상, 폐렴이 주 증상으로 나타나지만 무증상 감염 사례도 드물게 나오고 있다.Recently, the novel coronavirus (COVID-19, SARS-CoV-2), the causative virus of a new infectious disease that occurred in December 2019, has become a social problem. The new coronavirus is one of the seven coronaviruses that infect humans, and is reported to be transmitted when droplets from an infected person penetrate the respiratory tract or mucous membranes of the eyes, nose, and mouth. After an incubation period of approximately 2 to 14 days (estimated), the main symptoms are fever, respiratory symptoms such as coughing or difficulty breathing, and pneumonia, but cases of asymptomatic infection are also rare.
바이러스 감염을 예방하는 가장 좋은 방법은 백신접종이다. 그러나, 백신은 항상 이용될 수 있는 것이 아니고, 충분한 백신 보급률을 가진 후진국에서는 상당한 과제일 수 있다. 더욱이, 일단 감염되면, 백신접종은 더 이상 유용하지 않고, 면역 시스템이 감염과 싸우는 것을 돕기 위해 약물이 필요하다.The best way to prevent viral infection is vaccination. However, vaccines are not always available and can be a significant challenge in underdeveloped countries with sufficient vaccine coverage. Moreover, once infected, vaccination is no longer useful and medications are needed to help the immune system fight the infection.
최근 발생한 신종코로나바이러스(COVID-19, SARS-CoV-2)에 특이적인 치료법이나 감염 억제를 위해 사용할 수 있는 특이적인 항바이러스제 및 백신도 없는 실정이므로 감염 예방만을 강조하고 있는 실정이다.Since there is no specific treatment for the recently emerged new coronavirus (COVID-19, SARS-CoV-2), or a specific antiviral agent or vaccine that can be used to suppress infection, only infection prevention is being emphasized.
이에 본 발명자들은 퓨리톤으로 명명하고 개발한 특정 성분 및 함량으로 구성된 미네랄 이온 혼합물이 상기 신종코로나바이러스 등의 바이러스를 사멸하는데 중요한 역할을 하는 것을 발견하고, 본 발명을 완성하게 되었다.Accordingly, the present inventors discovered that a mineral ion mixture composed of specific ingredients and contents, named and developed as Puritone, plays an important role in killing viruses such as the novel coronavirus, and completed the present invention.
삭제delete
본 발명의 하나의 목적은 특정 성분 및 함량의 미네랄 이온 혼합물을 유효성분으로 포함하는 살바이러스 조성물을 제공하는 것이다.One object of the present invention is to provide a virus-killing composition containing a mineral ion mixture of a specific composition and content as an active ingredient.
본 발명의 다른 하나의 목적은 상기 조성물을 포함하는 살바이러스용 약학적 조성물을 제공하는 것이다.Another object of the present invention is to provide a pharmaceutical composition for killing viruses containing the composition.
본 발명의 다른 하나의 목적은 상기 조성물을 포함하는 살바이러스용 식품 조성물을 제공하는 것이다.Another object of the present invention is to provide a food composition for killing viruses containing the composition.
본 발명의 다른 하나의 목적은 살바이러스 및/또는 바이러스 예방을 위한 상기 살바이러스 조성물의 용도를 제공하는 것이다.Another object of the present invention is to provide a use of the virus killing composition for killing viruses and/or preventing viruses.
하나의 양태로서, 본 발명은 미네랄 이온 혼합물을 유효성분으로 포함하는 살바이러스 조성물을 제공한다.In one aspect, the present invention provides a virus killing composition comprising a mineral ion mixture as an active ingredient.
본 발명에 있어서, 상기 미네랄 이온 혼합물은 바이오타이트(Biotite), 카올리나이트(Kaolinite), 몬트모릴로나이트(Montmorillonite), 서펜틴(Serpentine), 마이카(Mica), 제올라이트(Zeolite), 클리노클로레(Clinochlore), 버미쿨라이트(Vermiculite), 무스코바이트(Muscovite), 브루사이트(Brucite), 리메스톤(Limestone), 일라이트(Illite), 올소클레이스(Orthoclase) 또는 올소클레이스 펠드스파(Orthoclase feldspar), 베마이트(boehmite), 네펠린(Nepheline), 팔리코르스카이트(Palygorskite) 또는 애터펄자이트(Attapulgite), 마그네사이트(Magnesite), 스페릴라이트(Sperrylite), 크렌네라이트(Krennerite), 페트자이트(Petzite), 기브사이트(Gibbsite), 앨러페인(Allophane), 플로고파이트(Phlogopite), 레피도라이트(Lepidolite), 실바나이트(Sylvanite), 글로코나이트(Glauconite), 돌로마이트(Dolomite), 토르말린(Tourmaline), 카날라이트(Carnallite), 안드라다이트(Andradite) 및 휴마이트(Humite)로 이루어진 것을 특징으로 한다.In the present invention, the mineral ion mixture includes Biotite, Kaolinite, Montmorillonite, Serpentine, Mica, Zeolite, and Clinochlore ( Clinochlore, Vermiculite, Muscovite, Brucite, Limestone, Illite, Orthoclase or Orthoclase feldspar ), boehmite, Nepheline, Palygorskite or Attapulgite, Magnesite, Sperrylite, Krennerite, PET Petzite, Gibbsite, Allophane, Phlogopite, Lepidolite, Sylvanite, Glauconite, Dolomite, It is characterized by being composed of tourmaline, carnallite, andradite, and humite.
보다 구체적으로, 상기 미네랄 이온 혼합물은 하기 표 1에 나타낸 바와 같이 바이오타이트 18.4 중량%, 카올리나이트 16 중량%, 몬트모릴로나이트 13 중량%, 서펜틴 10 중량%, 마이카 7 중량%, 제올라이트 9 중량%, 클리노클로레 4 중량%, 버미쿨라이트 3 중량%, 무스코바이트 3 중량%, 브루사이트 1.4 중량%, 리메스톤 1 중량%, 일라이트 2 중량%, 올소클레이스 또는 올소클레이스 펠드스파 1 중량%, 베마이트 0.9 중량%, 네펠린 0.8 중량%, 팔리코르스카이트 또는 애터펄자이트 0.8 중량%, 마그네사이트 0.7 중량%, 스페릴라이트 0.6 중량%, 크렌네라이트 0.6 중량%, 페트자이트 0.5 중량%, 기브사이트 0.4 중량%, 앨러페인 1 중량%, 플로고파이트 0.4 중량%, 레피도라이트 0.3 중량%, 실바나이트 0.3 중량%, 글로코나이트 0.3 중량%, 돌로마이트 1.3 중량%, 토르말린 1.8 중량%, 카날라이트 0.2 중량%, 안드라다이트 0.2 중량% 및 휴마이트 0.1 중량%로 이루어진 것을 특징으로 한다. More specifically, the mineral ion mixture is 18.4% by weight of biotite, 16% by weight of kaolinite, 13% by weight of montmorillonite, 10% by weight of serpentine, 7% by weight of mica, and 9% by weight of zeolite, as shown in Table 1 below. , 4% by weight of clinochlore, 3% by weight of vermiculite, 3% by weight of muscovite, 1.4% by weight of brushite, 1% by weight of rimestone, 2% by weight of illite, orthoclais or orthoclais feldspar. 1% by weight, boehmite 0.9% by weight, nepheline 0.8% by weight, palikorskite or attapulgite 0.8% by weight, magnesite 0.7% by weight, spherylite 0.6% by weight, crennelite 0.6% by weight, petzite 0.5% by weight of gibbsite, 0.4% by weight of alephane, 1% by weight of phlogopite, 0.4% by weight of lepidolite, 0.3% by weight of sylvanite, 0.3% by weight of glauconite, 1.3% by weight of dolomite, tourmaline It is characterized in that it consists of 1.8% by weight, 0.2% by weight of canalite, 0.2% by weight of andradite, and 0.1% by weight of humite.
본 발명의 상기 미네랄 이온 혼합물은 본 발명자가 약 20여년 전부터 광물의학을 토대로 연구 개발한 100% 광물성 천연물질을 기초로 성분 및 함량을 달리한 혼합물로서, 이러한 혼합물에 대하여 '퓨리톤(puriton)'으로 명명하여 사용하여 왔다. 따라서 본 명세서에서도 상기 미네랄 이온 혼합물을 '퓨리톤(puriton)'이라 칭하고 사용한다.The mineral ion mixture of the present invention is a mixture of different components and contents based on 100% mineral natural substances that the present inventor has researched and developed based on mineral medicine for about 20 years. This mixture is called 'puriton'. It has been named and used. Therefore, in this specification, the mineral ion mixture is referred to and used as 'puriton'.
상기 '퓨리톤'은 미국 FDA로부터 성분분석, 독성분석, 영양분석을 통과해서 인체내(눈, 간, 피부) 모든 부분에 안전성을 인정받았으며, 일반의약품(NDC)으로 승인을 받은 바 있다. 현재 출시한 제품은 5가지의 일반 의약품이 있다. 퓨리톤 안약(Puriton Eye Relief Drop), 얼굴치료, 피부치료, 화상 절상 등 응급처치, 여성 청결치료제 등이다. 다만, 상기 출시한 제품의 성분 및 함량은 본 명세서의 조성물과는 상이하다.The 'Puriton' has been recognized as safe for all parts of the human body (eyes, liver, skin) by passing ingredient analysis, toxicity analysis, and nutritional analysis by the U.S. FDA, and has been approved as an over-the-counter drug (NDC). Currently, there are five general medicines released on the market. These include Puriton Eye Relief Drop, facial treatment, skin treatment, first aid such as burn cuts, and feminine cleanliness treatment. However, the ingredients and content of the above-mentioned product are different from the composition described in this specification.
퓨리톤 안약(Puriton Eye Drop)은 눈건조증에 대해 높은 치료 효능을 보일 뿐만 아니라 불치에 가까운 눈질환인 백내장, 녹내장, 비문증 등의 질환치료에 이르기까지 효능을 나타낸다고 알려졌다. 또한, 퓨리톤 여성 청결치료제(puriton Intimate Disinfection Spray)는 대부분 여성의 깊은 고민으로 자리하고 있는 질염 및 방광염과 일반적 치질에 이르기까지 그 질환의 균을 완벽하게 잡아줌으로써 극대의 치료효능을 가진 신개념 의약품이라 할 수 있다. 액상형태로서 시판되는 것을 구입하여 사용하거나 직접 제조하여 사용할 수 있다. 다만, 상기 출시한 제품의 성분 및 함량은 본 명세서의 조성물과는 상이하다.Puriton Eye Drop is known not only to have high therapeutic efficacy for dry eyes, but also to treat nearly incurable eye diseases such as cataracts, glaucoma, and rhinorrhea. In addition, Puriton Intimate Disinfection Spray is a new concept medicine with maximum therapeutic efficacy by completely eliminating the germs of diseases ranging from vaginitis and cystitis to general hemorrhoids, which are deep concerns of most women. can do. It can be purchased and used commercially in liquid form or manufactured and used directly. However, the ingredients and content of the above-mentioned product are different from the composition described in this specification.
퓨리톤은 천연광물로 점토계 원료인 고령토, 벤토나이트, 제올라이트, 탄산칼슘, 운모류 등의 광물을 이용하여 제조될 수 있는데, 이들 광물은 분쇄전 900℃이상의 고온소성을 거쳐 원료내에 함유된 유해 불순물 및 중금속 등을 제거하는 공정을 거친다. 소성공정을 마친 원료를 분쇄공정을 통해 원하는 미세한 나노입자의 광물로 가공처리를 하게 된다. 상기 분쇄는 건식 또는 습식 또는 이들을 순차적으로 혼합한 방식으로 이루어질 수 있다. 건식공정에서는 정밀한 미세입자의 생산성은 낮으며 단계별로 미세한 입자를 얻을 수 있으나 대량적인 생산에 한계가 있고 정밀성이 떨어진다. 반면 습식공정은 준비된 광물을 볼밀에 준비된 광물을 투입하여 적당량의 물을 투입하여 고속의 회전을 가하여 미분말을 얻을 수 있는 아주 미세하고 정밀한 입자를 대량적으로 생산할 수 있으나 제조비용이 건식에 비해 높은 단점이 있다. 일반적으로 퓨리톤 액상 제조에 투입되는 광물의 입자크기는 나노입자에 해당되는 5000 mesh(2㎛ 이하)이상의 아주 미세한 분말을 사용한다.Puritone is a natural mineral that can be manufactured using clay-based minerals such as kaolin, bentonite, zeolite, calcium carbonate, and mica. These minerals are calcined at a high temperature of over 900℃ before grinding to remove harmful impurities and It goes through a process to remove heavy metals, etc. After completing the firing process, the raw materials are processed into the desired fine nanoparticle mineral through a grinding process. The grinding may be performed dry or wet, or by sequentially mixing them. In the dry process, the productivity of precise fine particles is low, and although fine particles can be obtained in stages, there are limits to mass production and precision is poor. On the other hand, the wet process can produce very fine and precise particles in large quantities by putting the prepared minerals into a ball mill, adding an appropriate amount of water and rotating at high speed to obtain fine powder, but the manufacturing cost is higher than the dry process. There is. In general, the particle size of the mineral used in the production of Puriton liquid is very fine powder of 5000 mesh (2㎛ or less) or more, which corresponds to nanoparticles.
퓨리톤의 원료는 식품 및 의약품의 용도로서 수많은 종류의 콜로이드성 미네랄이 함유된 몬모릴로나이트(Montmorillonites) 또는 벤토나이트(Bentonite) 등을 주요 구성물로 하는 안정된 점토광물을 주요성분 원료로 사용한다. 점토광물의 주원소는 Si, Al, Na, K, Ti이며 미량원소는 많은 원소 가운데 Fe, Ca, S, Mg, Ce, La, Zr, P 등이며 바이오세라믹 분말은 Fe2O3, TiO2, Na2O, SiO2, P2O5, CeO2, K2O, MgO 등이다. 퓨리톤의 특성은 몬모릴로나이트(또는 벤토나이트)인 점토광물을 미세한 입자크기로 분쇄한 후 콜로이드 상태로 정제처리한 수많은 미량원소(Trace minerals)가 함유된 복합물질이다. 그리고 혈액세포보다 입자크기가 훨씬 작은 천연상태(Colloidal Trace Minerals)의 미네랄이다. 종합하면 점토광물로서 의학적 광물학(Medical Mineralogy)에서 인정된 점토광물이 퓨리톤의 주원료이다.Puriton's raw materials are used for food and pharmaceutical purposes, and its main ingredient is a stable clay mineral containing Montmorillonites or Bentonite, which contain numerous types of colloidal minerals. The main elements of clay minerals are Si, Al, Na, K, and Ti, and trace elements include Fe, Ca, S, Mg, Ce, La, Zr, and P, among many other elements, and bioceramic powders include Fe 2 O 3 and TiO 2 , Na 2 O, SiO 2 , P 2 O 5 , CeO 2 , K 2 O, MgO, etc. The characteristics of Puriton are that it is a complex material containing numerous trace minerals (trace minerals) made by pulverizing the clay mineral called montmorillonite (or bentonite) into fine particle sizes and then purifying it into a colloidal state. And they are minerals in their natural state (Colloidal Trace Minerals) whose particle size is much smaller than that of blood cells. In summary, clay minerals recognized in Medical Mineralogy are the main raw materials of Puritone.
습식분쇄된 나노입자의 미분말 광물질을 고온 고압 공정장치에 적당량의 광물분말과 증류수를 투입하여 밀폐된 개방형 혼합기에 투입하여 수행한다. 100 내지 300℃의 열을 가하여 투입된 광물과 물이 고온에서 반응하여 인체에 필수적인 이온화된 미네랄을 용출시키는 공정이며 적정 가열시간을 부여하여 인체에 필요한 다량의 광물성 미네랄을 얻게 된다. 미네랄 용출공정을 거친 후 숙성공정인 광물의 침전과정을 거친다. 그 과정의 부여시간은 액상내에 이온화된 광물의 입자크기에 영향을 미친다. 대략적으로 숙성공정은 원하는 제품에 따라 24시간에서 일주일 이상의 숙성시간이 필요하다.This is carried out by adding an appropriate amount of mineral powder and distilled water to a high-temperature, high-pressure process equipment for wet-ground finely powdered nanoparticles and then putting them in a closed, open mixer. This is a process in which ionized minerals essential to the human body are eluted by applying heat of 100 to 300°C so that the added minerals and water react at high temperature to elute ionized minerals essential to the human body. By providing an appropriate heating time, a large amount of minerals necessary for the human body are obtained. After going through the mineral elution process, it goes through the mineral precipitation process, which is a maturation process. The duration of the process affects the particle size of the ionized minerals in the liquid phase. Roughly speaking, the maturation process requires a maturation time of 24 hours to a week or more, depending on the desired product.
숙성과정이 마무리되면 콜로이드 액상과 침전된 광물의 미분말을 분리하는 필터링 공정을 거친다. 정밀한 필터링 공정을 통해 분리된 퓨리톤 미네랄 수용액을 제조할 수 있다.Once the maturation process is completed, it goes through a filtering process to separate the colloidal liquid from the fine powder of precipitated minerals. A separate puritone mineral aqueous solution can be produced through a precise filtering process.
본 발명에 따른 살바이러스 조성물은 바이러스의 세포막 및 핵을 분해시키며 단일가닥 RNA를 절단하여 바이러스 증식 억제 및 살바이러스 효과가 매우 탁월하다.The virus-killing composition according to the present invention decomposes the cell membrane and nucleus of the virus and cleaves single-stranded RNA, so it has excellent virus proliferation inhibition and virus killing effects.
본 발명에서 사용되는 용어 "바이러스 증식 억제"는 바이러스의 파괴와 상이한, 바이러스의 생장 및/또는 발생 및/또는 복제의 억제를 지칭한다. 전형적으로, 억제 효과는 바이러스 캡시드를 코팅하거나 세포 표면 수용체를 효과적으로 차단하여, 바이러스와 세포 사이의 상호작용에 대한 장벽을 생성함으로써 수득된다. 그러나, 바이러스는 활성 상태로 남아있고, 방출될 수 있고 세포를 감염시킬 수도 있다.As used herein, the term “inhibition of viral growth” refers to inhibition of the growth and/or development and/or replication of a virus, which is different from destruction of the virus. Typically, the inhibitory effect is obtained by coating the viral capsid or effectively blocking cell surface receptors, creating a barrier to interaction between the virus and the cell. However, the virus remains active and can be released and infect cells.
본 발명에서 사용되는 용어 "살바이러스"는 바이러스의 중화 및/또는 파괴를 지칭한다. 살바이러스 조성물과의 상호작용은 바이러스를 변경시키고 바이러스를 불활성 상태로 만들어, 추가 감염을 예방한다.As used herein, the term “virulicide” refers to neutralization and/or destruction of viruses. Interaction with the virucidal composition alters the virus and renders it inactive, preventing further infection.
본 발명에서 사용되는 용어 "생체적합성"은 살아있는 세포, 조직, 장기 또는 시스템에 적합하고 손상, 독성 또는 면역 시스템에 의한 거부의 위험을 갖지 않는다는 것을 의미한다.As used herein, the term “biocompatible” means compatible with living cells, tissues, organs or systems and without risk of damage, toxicity or rejection by the immune system.
본 발명에 있어서, 상기 바이러스는 단일가닥 RNA 바이러스인 것을 특징으로 한다. 상기 단일가닥 RNA 바이러스는 반드시 이로 제한되는 것은 아니지만, 소아마비와 관련된 폴리오바이러스(poliovirus) 등, 무균성 뇌수막염과 관련된 콕사키바이러스, 에코바이러스, 멈프스바이러스 등, 수족구병과 관련된 A군 콕사키바이러스, 엔테로바이러스 71형, B군 콕사키바이러스, 에코바이러스 등, 헤르페스목구멍염(Herpangina)과 관련된 A군 콕사키, 에코바이러스 등, 급성 출혈성 결막염과 관련된 엔테로바이러스 70형, 유행성 가슴막통증과 관련된 B군 콕사키바이러스, 가성콜레라(로타바이러스 감염증)과 관련된 로타바이러스, 풍진(rubella)과 관련된 루벨라바이러스(풍진바이러스), 급성 호흡기 질환과 관련된 코로나바이러스로 중증 급성 호흡기 증후군 코로나바이러스(SARS-CoV), 중동 호흡기 증후군 코로나바이러스(MERS-CoV), 신종코로나바이러스(COVID-19, SARS-CoV-2) 등이 있다. 바람직하게는 급성 호흡기 질환과 관련된 코로나바이러스로 중증 급성 호흡기 증후군 코로나바이러스(SARS-CoV), 중동 호흡기 증후군 코로나바이러스(MERS-CoV), 신종코로나바이러스(COVID-19, SARS-CoV-2)이다.In the present invention, the virus is characterized as a single-stranded RNA virus. The single-stranded RNA viruses are not necessarily limited to this, but include poliovirus associated with polio, coxsackievirus, echovirus, and mupsvirus associated with aseptic meningitis, group A coxsackievirus associated with hand, foot, and mouth disease, and enterovirus. Virus type 71, group B coxsackievirus, echovirus, etc., group A coxsackievirus, echovirus, etc. related to herpangina, enterovirus type 70 related to acute hemorrhagic conjunctivitis, group B coxsack associated with epidemic pleurisy Saki virus, rotavirus related to pseudocholera (rotavirus infection), rubella virus related to rubella, severe acute respiratory syndrome coronavirus (SARS-CoV), a coronavirus related to acute respiratory disease, Middle East These include respiratory syndrome coronavirus (MERS-CoV) and novel coronavirus (COVID-19, SARS-CoV-2). Preferably, coronaviruses related to acute respiratory diseases include severe acute respiratory syndrome coronavirus (SARS-CoV), Middle East respiratory syndrome coronavirus (MERS-CoV), and novel coronaviruses (COVID-19, SARS-CoV-2).
본 발명의 상기 살바이러스 조성물은 화장료 조성물 또는 약학적 조성물일 수 있다.The virus killing composition of the present invention may be a cosmetic composition or a pharmaceutical composition.
본 발명에 있어서, 상기 “유효성분”이란 단독으로 목적하는 활성을 나타내거나 또는 그 자체는 활성이 없는 담체와 함께 활성을 나타낼 수 있는 성분을 의미한다.In the present invention, the “active ingredient” refers to an ingredient that exhibits the desired activity alone or can exhibit activity in combination with a carrier that is not active on its own.
본 발명의 조성물은 조성물의 총 중량을 기준으로 하여 퓨리톤이 0.005 내지 50 중량%, 보다 바람직하게는 0.01 내지 30 중량%, 가장 바람직하게는 0.1 내지 10 중량%로 포함할 수 있다. 이 때 퓨리톤의 함량이 0.005 중량% 미만일 경우 본 발명의 목적효과인 살바이러스 효과를 수득할 수 없으며, 50 중량%를 초과할 경우 함량의 증가에 따라 효과가 비례적이지 않아 비효율적일 수 있으며 제형상의 안정성이 확보되지 않는 문제점이 있다.The composition of the present invention may contain puritone in an amount of 0.005 to 50% by weight, more preferably 0.01 to 30% by weight, and most preferably 0.1 to 10% by weight, based on the total weight of the composition. At this time, if the puritone content is less than 0.005% by weight, the virus-killing effect, which is the objective effect of the present invention, cannot be obtained, and if it exceeds 50% by weight, the effect may not be proportional as the content increases, making it inefficient. There is a problem in that the stability of the shape is not secured.
본 발명의 하나의 실시양태에 따르면, 상기 미네랄 이온 혼합물을 유효성분으로 포함하는 화장료 조성물을 제공한다.According to one embodiment of the present invention, a cosmetic composition containing the mineral ion mixture as an active ingredient is provided.
본 발명의 하나의 실시양태에 따른 화장료 조성물은 유효성분으로서 상기 미네랄 이온 혼합물 이외에 화장품 조성물에 통상적으로 첨가되는 성분, 예컨대 항산화제, 안정화제, 가용화제, 비타민, 안료 및 향료와 같은 통상적인 보조제, 및 담체를 추가로 첨가할 수 있다.The cosmetic composition according to one embodiment of the present invention contains, as an active ingredient, in addition to the mineral ion mixture, ingredients commonly added to cosmetic compositions, such as antioxidants, stabilizers, solubilizers, vitamins, conventional auxiliaries such as pigments and fragrances, And a carrier may be additionally added.
본 발명의 화장료 조성물은 당업계에서 통상적으로 제조되는 어떠한 제형으로도 제조될 수 있으며, 예를 들어, 용액, 현탁액, 유탁액, 페이스트, 겔, 크림, 로션, 파우더, 비누, 계면활성제-함유 클린싱, 오일, 분말 파운데이션, 유탁액 파운데이션, 왁스 파운데이션 및 스프레이 등으로 제형화될 수 있으나, 이에 한정되는 것은 아니다. 보다 상세하게는, 영양 크림, 수렴 화장수, 유연 화장수, 로션, 에센스, 영양젤 또는 마사지 크림의 제형으로 제조될 수 있다.The cosmetic composition of the present invention can be prepared in any formulation commonly prepared in the art, for example, solutions, suspensions, emulsions, pastes, gels, creams, lotions, powders, soaps, surfactant-containing cleansing agents. , oil, powder foundation, emulsion foundation, wax foundation, spray, etc., but is not limited thereto. More specifically, it can be manufactured in the form of nutritional cream, astringent lotion, softening lotion, lotion, essence, nutritional gel, or massage cream.
본 발명의 제형이 페이스트, 크림 또는 겔인 경우에는 담체 성분으로서 동물성유, 식물성유, 왁스, 파라핀, 전분, 트라칸트 검, 셀룰로오스 유도체, 폴리에틸렌 글리콜, 실리콘, 벤토나이트, 실리카, 탈크 또는 산화아연 등이 이용될 수 있다.When the formulation of the present invention is a paste, cream or gel, animal oil, vegetable oil, wax, paraffin, starch, gum tracant, cellulose derivative, polyethylene glycol, silicone, bentonite, silica, talc or zinc oxide are used as carrier ingredients. It can be.
본 발명의 제형이 파우더 또는 스프레이인 경우에는 담체 성분으로서 토스, 탈크, 실리카, 알루미늄 히드록시드, 칼슘 실리케이트 또는 폴리아미드 파우더가 이용될 수 있고, 특히 스프레이인 경우에는 추가적으로 클로로플루오로히드로카본, 프로판/부탄 또는 디메틸에테르와 같은 추진체를 포함할 수 있다.When the formulation of the present invention is a powder or spray, toss, talc, silica, aluminum hydroxide, calcium silicate, or polyamide powder can be used as the carrier component. In particular, when the formulation is a spray, chlorofluorohydrocarbon and propane may be used as carrier ingredients. /May contain propellants such as butane or dimethyl ether.
본 발명의 제형이 용액 또는 유탁액인 경우에는 담체 성분으로서 용매, 가용화제 또는 유탁화제가 이용되고, 예컨대 물, 에탄올, 이소프로판올, 에틸 카보네이트, 에틸 아세테이트, 벤질 알코올, 벤질 벤조에이트, 프로필렌글리콜, 1,3-부틸글리콜 오일, 글리세롤 지방족 에스테르, 폴리에틸렌 글리콜 또는 소르비탄의 지방산 에스테르가 있다.When the formulation of the present invention is a solution or emulsion, a solvent, solubilizer or emulsifier is used as a carrier component, such as water, ethanol, isopropanol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1 , 3-butyl glycol oil, glycerol aliphatic esters, polyethylene glycol or fatty acid esters of sorbitan.
본 발명의 제형이 현탁액인 경우에는 담체 성분으로서 물, 에탄올 또는 프로필렌 글리콜과 같은 액상의 희석제, 에톡실화 이소스테아릴 알코올, 폴리옥시에틸렌 소르비톨 에스테르 및 폴리옥시에틸렌 소르비탄 에스테르와 같은 현탁제, 미소결정성 셀룰로오스, 알루미늄 메타히드록시드, 벤토나이트, 아가 또는 트라칸트 검등이 이용될 수 있다.When the formulation of the present invention is a suspension, the carrier ingredients include water, a liquid diluent such as ethanol or propylene glycol, a suspending agent such as ethoxylated isostearyl alcohol, polyoxyethylene sorbitol ester, and polyoxyethylene sorbitan ester, and microcrystals. Cellulose, aluminum metahydroxide, bentonite, agar or tracant gum can be used.
본 발명의 제형이 계면-활성제 함유 클린징인 경우에는 담체 성분으로서 지방족 알코올 설페이트, 지방족 알코올 에테르 설페이트, 설포숙신산 모노에스테르, 이세티오네이트, 이미다졸리늄 유도체, 메틸타우레이트, 사르코시네이트, 지방산 아미드 에테르 설페이트, 알킬아미도베타인, 지방족 알코올, 지방산 글리세리드, 지방산 디에탄올아미드, 식물성 유, 라놀린 유도체 또는 에톡실화 글리세롤 지방산 에스테르 등이 이용될 수 있다.When the formulation of the present invention is a surfactant-containing cleansing agent, the carrier ingredients include aliphatic alcohol sulfate, aliphatic alcohol ether sulfate, sulfosuccinic acid monoester, isethionate, imidazolinium derivative, methyl taurate, sarcosinate, and fatty acid amide. Ether sulfate, alkylamidobetaine, fatty alcohol, fatty acid glyceride, fatty acid diethanolamide, vegetable oil, lanolin derivative, or ethoxylated glycerol fatty acid ester can be used.
본 발명의 하나의 실시양태에 따르면, 상기 미네랄 이온 혼합물을 유효성분으로 포함하는 약학적 조성물을 제공한다.According to one embodiment of the present invention, a pharmaceutical composition comprising the mineral ion mixture as an active ingredient is provided.
본 발명의 조성물이 약학적 조성물로 사용되는 경우, 유효성분으로서 상기 미네랄 이온 혼합물 이외에 약학적으로 허용되는 담체를 추가로 포함할 수 있다. 본 발명의 약학적 조성물에 포함되는 약학적으로 허용되는 담체는 제제시에 통상적으로 이용되는 것으로서, 탄수화물류 화합물(예: 락토스, 아밀로스, 덱스트로스, 수크로스, 솔비톨, 만니톨, 전분, 셀룰로스 등), 아카시아 고무, 인산 칼슘, 알기네이트, 젤라틴, 규산 칼슘, 미세결정성 셀룰로스, 폴리비닐피롤리돈, 셀룰로스, 물, 시럽, 염 용액, 알코올, 아라비아 고무, 식물성 기름(예: 옥수수 기름, 목화 종자유, 두유, 올리브유, 코코넛유), 폴리에틸렌 글리콜, 메틸 셀룰로스, 메틸히드록시 벤조에이트, 프로필히드록시 벤조에이트, 활석, 스테아르산 마그네슘 및 미네랄 오일 등을 포함하나, 이에 한정되는 것은 아니다. 본 발명의 약학적 조성물은 상기 성분들 이외에 윤활제, 습윤제, 감미제, 향미제, 유화제, 현탁제, 보존제 등을 추가로 포함할 수 있다. 적합한 약학적으로 허용되는 담체 및 제제는 Remington's Pharmaceutical Sciences (19th ed., 1995)에 상세히 기재되어 있다.When the composition of the present invention is used as a pharmaceutical composition, it may further include a pharmaceutically acceptable carrier in addition to the mineral ion mixture as an active ingredient. Pharmaceutically acceptable carriers included in the pharmaceutical composition of the present invention are those commonly used in preparation, and include carbohydrate compounds (e.g. lactose, amylose, dextrose, sucrose, sorbitol, mannitol, starch, cellulose, etc.) , acacia gum, calcium phosphate, alginate, gelatin, calcium silicate, microcrystalline cellulose, polyvinylpyrrolidone, cellulose, water, syrup, salt solution, alcohol, gum arabic, vegetable oils (e.g. corn oil, cotton seed oil) , soy milk, olive oil, coconut oil), polyethylene glycol, methyl cellulose, methyl hydroxy benzoate, propyl hydroxy benzoate, talc, magnesium stearate, and mineral oil, but are not limited thereto. In addition to the above ingredients, the pharmaceutical composition of the present invention may further include lubricants, wetting agents, sweeteners, flavoring agents, emulsifiers, suspending agents, preservatives, etc. Suitable pharmaceutically acceptable carriers and formulations are described in detail in Remington's Pharmaceutical Sciences (19th ed., 1995).
본 발명의 약학적 조성물의 바람직한 투여량은 성인 기준으로 0.001 내지 100 ㎎/kg 범위 내이다. 또한 외용제인 경우에는 성인 기준으로 1.0 내지 3.0 ml의 양으로 1일 1회 내지 5회 도포하여 1개월 이상 계속하는 것이 좋다. 상기 투여량은 본 발명의 범위를 한정하는 것이 아니다.The preferred dosage of the pharmaceutical composition of the present invention is within the range of 0.001 to 100 mg/kg for adults. In addition, in the case of external use, it is recommended to apply 1.0 to 3.0 ml for adults once to 5 times a day and continue for more than 1 month. The above dosage does not limit the scope of the present invention.
본 발명의 약학적 조성물의 제형으로는 통상의 방법에 따라 산제, 과립제, 정제, 캡슐제, 에멀젼, 시럽, 에어로졸 등의 경구형 제형, 연고, 크림 등의 외용제 및 멸균 주사용액 등을 비롯하여 약학적 제제에 적합한 어떠한 형태로든 제형화하여 사용할 수 있다.The formulation of the pharmaceutical composition of the present invention includes oral formulations such as powders, granules, tablets, capsules, emulsions, syrups, and aerosols, external preparations such as ointments and creams, and sterilized injection solutions, as well as pharmaceutical formulations according to conventional methods. It can be formulated and used in any form suitable for the preparation.
본 발명의 살바이러스용 약학적 조성물이 피부 외용제로 제공될 경우, 이에 제한되는 것은 아니나, 연고, 패취, 겔, 크림 또는 분무제 등의 제형일 수 있다.When the pharmaceutical composition for killing viruses of the present invention is provided as an external skin preparation, it is not limited thereto, but may be in the form of an ointment, patch, gel, cream, or spray.
본 발명의 살바이러스 조성물은 바이러스, 특히 단일가닥 RNA 바이러스에 대한 우수한 살바이러스 효과가 있으며, 그 유효성분이 점토광물로서 의학적 광물학(Medical Mineralogy)에서 인정된 점토광물이므로 세포 독성이 없이 인체 피부에 안전하다.The virus killing composition of the present invention has an excellent virus killing effect against viruses, especially single-stranded RNA viruses, and its active ingredient is a clay mineral recognized in Medical Mineralogy, so it is non-cytotoxic and safe for human skin. .
따라서, 본 발명에 따른 살바이러스 조성물은 상기 의약품 및 화장품 이외에도 바이러스를 살균하거나 예방을 목적으로 하는 다양한 제품, 예를 들어 섬유, 생활용품, 주방용품 등에서 살바이러스 목적을 달성하기 위해 광범위하게 사용될 수 있으며, 이들 제품에 사용되어 제품의 품질의 안전성과 안정성을 높이는 효과가 있다. 특히, 본 발명의 살바이러스 조성물은 액상의 형태로 사용 가능하므로 사용 시 도포 또는 접촉 등의 용이한 방법으로도 살바이러스의 목적으로 사용할 수 있다.Therefore, the virus-killing composition according to the present invention can be widely used to achieve the purpose of killing viruses in various products for the purpose of sterilizing or preventing viruses, such as textiles, household goods, kitchenware, etc., in addition to the medicines and cosmetics. , When used in these products, it has the effect of increasing the safety and stability of product quality. In particular, the virus-killing composition of the present invention can be used in liquid form, so it can be used for virus-killing purposes by easy methods such as application or contact.
상기한 제품에 본 발명의 살바이러스 조성물을 포함시키는 경우, 이의 사용량은 제품의 총 중량을 기준으로 하여 0.001 내지 30 중량%, 바람직하게는 0.001 내지 20 중량 %, 보다 바람직하게는 0.001 내지 5 중량%의 범위이다.When the virus killing composition of the present invention is included in the above product, the amount used is 0.001 to 30% by weight, preferably 0.001 to 20% by weight, more preferably 0.001 to 5% by weight, based on the total weight of the product. is the range.
본 발명의 살바이러스 조성물을 포함하는 제품을 제조하기 위해, 당업자에게 널리 공지된 바에 따라 적합한 제형 및 첨가제를 선택하여 이를 제조할 수 있을 것이다.In order to manufacture a product containing the virus-killing composition of the present invention, it can be prepared by selecting a suitable formulation and additives according to what is well known to those skilled in the art.
또한, 본 발명에 따른 살바이러스 조성물은 살바이러스용 소독제로서 사용할 수 있다. 상기 살바이러스 소독제는 본 발명의 살바이러스 조성물이 전체 조성물에서 30 내지 100중량%로 하유될 수 있다.Additionally, the virus killing composition according to the present invention can be used as a virus killing disinfectant. The virus killing disinfectant may contain 30 to 100% by weight of the virus killing composition of the present invention based on the total composition.
본 발명에 따른 살바이러스 조성물은 바이러스, 특히 단일가닥 RNA 바이러스에 대한 바이러스 증식 억제 및 살바이러스 효과가 매우 우수하고, 그 유효성분이 점토광물로서 의학적 광물학(Medical Mineralogy)에서 인정된 점토광물이므로 세포 독성이 없이 인체 피부에 안전하므로 바이러스를 살균하거나 예방을 목적으로 하는 다양한 제품, 예를 들어 의약품, 화장품, 섬유, 생활용품, 주방용품 등에 유용하게 사용할 수 있다.The virus killing composition according to the present invention has excellent virus proliferation inhibition and virus killing effects against viruses, especially single-stranded RNA viruses, and its active ingredient is a clay mineral recognized in Medical Mineralogy, so it has no cytotoxicity. Since it is safe for human skin, it can be usefully used in various products aimed at sterilizing or preventing viruses, such as medicines, cosmetics, textiles, household goods, and kitchenware.
도 1은 본 발명의 일 실시예에 따른 본 발명의 조성물에 대한 hCoV-OC43 코로나 바이러스의 살바이러스 효과를 나타낸 그림이다. 여기서, 로그 감소값(log reduction value)은 음성 대조군(물)과 비교하여 나타내었다.
도 2는 본 발명의 일 실시예에 따른 본 발명의 조성물에 대한 SARS-CoV-2(COVID-19) 코로나 바이러스의 살바이러스 효과를 나타낸 그림이다. 여기서, 로그 감소값(log reduction value)은 음성 대조군(물)과 비교하여 나타내었다.Figure 1 is a diagram showing the virus killing effect of the hCoV-OC43 coronavirus on the composition of the present invention according to an embodiment of the present invention. Here, the log reduction value is expressed compared to the negative control (water).
Figure 2 is a diagram showing the virucidal effect of the composition of the present invention on the SARS-CoV-2 (COVID-19) coronavirus according to an embodiment of the present invention. Here, the log reduction value is expressed compared to the negative control (water).
이하, 본 발명의 이해를 돕기 위하여 실시예 등을 들어 상세하게 설명하기로 한다. 그러나, 본 발명에 따른 실시예들은 여러 가지 다른 형태로 변형될 수 있으며, 본 발명의 범위가 하기 실시예들에 한정되는 것으로 해석되어서는 안 된다. 본 발명의 실시예들은 당업계에서 평균적인 지식을 가진 자에게 본 발명을 보다 완전하게 설명하기 위해 제공되는 것이다.Hereinafter, to aid understanding of the present invention, it will be described in detail through examples. However, the embodiments according to the present invention may be modified into various other forms, and the scope of the present invention should not be construed as being limited to the following embodiments. Embodiments of the present invention are provided to more completely explain the present invention to those skilled in the art.
실시예Example 1: One: hCoVOChCoVOC 43에 대한 for 43 퓨리톤의puriton's 살바이러스killing virus 효과 effect
하기 표 1과 같은 조성의 퓨리톤이 인간 코로나 바이러스 (hCoV-OC43)에 미치는 영향을 확인하기 위하여 유타주립대학교 (Utah State University)의 항바이러스 연구소(Institute for Antiviral Research)에 의뢰하여 하기와 같은 방법으로 실험하였다.In order to confirm the effect of puritone of the composition shown in Table 1 below on human coronavirus (hCoV-OC43), the Institute for Antiviral Research at Utah State University was contacted and the method was used as follows. was tested.
[표 1][Table 1]
구체적으로, 인간 코로나 바이러스 (hCoV-OC43) 스톡(stock)은 2% FBS 및 50 μg/mL 젠타마이신(gentamicin)을 포함하는 MEM 배지에서 준비하였다. 상기 hCoV-OC43 바이러스는 현재 코로나바이러스 질환(COVID-10)을 일으키는 코로나 바이러스와 같은 베타 타입이다.Specifically, human coronavirus (hCoV-OC43) stock was prepared in MEM medium containing 2% FBS and 50 μg/mL gentamicin. The hCoV-OC43 virus is the same beta type as the coronavirus that currently causes coronavirus disease (COVID-10).
상기 퓨리톤 용액을 90 % 및 70 %의 농도로 희석한 후 이를 3중 튜브에 넣은 후 상기 준비된 바이러스 스톡을 첨가하였다. 독성(toxicity) 및 중화(neutralization) 대조군으로 사용하기 위해 각 준비된 농도의 하나의 튜브에만 상기 바이러스 스톡을 첨가하였다. 에탄올 (70%)은 양성 대조군으로 실험하였으며, 음성 대조군으로 물만을 사용하였다.The puriton solution was diluted to a concentration of 90% and 70%, placed in a triple tube, and then the prepared virus stock was added. The virus stock was added to only one tube at each prepared concentration to be used as a toxicity and neutralization control. Ethanol (70%) was used as a positive control, and only water was used as a negative control.
바이러스 스톡이 첨가된 시료들을 실온에서 1 시간 및 6 시간 동안 배양하였다. 그 다음 각 시료를 배양 배지 (MEM + 5 % FBS + 50 μg/mL 젠타마이신)에서 1/10 희석하여 중화시켰다. 중화된 시료는 시험 배지에서 8 로그 희석을 사용하여 연속 희석하였다. 각 희석액을 80-100 % 컨플루언트 RD 세포가 있는 96-웰 플레이트의 4 개 웰에 첨가하였다. 독성 대조군을 추가적인 3 개의 웰에 추가하고 바이러스 (50 CCID50)로 감염시켜 중화 대조군으로 사용하였으며, 플레이트된(plated) 역가 분석(titer assay)에서 잔류 샘플이 생존 바이러스의 성장 및 검출을 억제하지 않도록 하였다. 모든 플레이트는 37 ± 2℃, 5 % CO2에서 배양하였다.Samples spiked with virus stock were incubated at room temperature for 1 hour and 6 hours. Each sample was then neutralized by dilution 1/10 in culture medium (MEM + 5% FBS + 50 μg/mL gentamicin). Neutralized samples were serially diluted in test medium using 8 log dilutions. Each dilution was added to 4 wells of a 96-well plate with 80-100% confluent RD cells. A virulence control was added to three additional wells and infected with virus (50 CCID50) to serve as a neutralization control, ensuring that residual samples did not inhibit growth and detection of viable virus in plated titer assays. . All plates were cultured at 37 ± 2°C and 5% CO 2 .
감염 후 6일째에 플레이트는 CPE(viral cytopathic effect)의 존재 또는 부재에 대해 점수를 매겼다. Reed-Muench 방법을 사용하여 샘플의 종점 역가 (50 % 세포 배양 감염 용량, CCID50)를 결정하였고 음성(물) 대조군과 비교한 화합물의 로그 감소값 (Log Reduction Value; LOR)을 계산하였다.At day 6 post infection, plates were scored for the presence or absence of viral cytopathic effect (CPE). The endpoint titer (50% cell culture infectious dose, CCID50) of the samples was determined using the Reed-Muench method and the log reduction value (LOR) of the compound compared to the negative (water) control was calculated.
hCoV-OC43에 대한 시료들의 바이러스 역가 및 LRV를 표 2 및 도 1에 나타내었다. 대조군 샘플의 바이러스는 2.4 ~ 2.8 log10 CCID50 이었으며, 바이러스 감소 검출을 1.7 ~ 2.1 log10 CCID50으로 제한하였다.The viral titers and LRV of the samples for hCoV-OC43 are shown in Table 2 and Figure 1. The virus in the control sample was 2.4 to 2.8 log 10 CCID50, and detection of virus reduction was limited to 1.7 to 2.1 log 10 CCID50.
70 % 및 90 %로 희석한 퓨리톤 용액 모두는 1/10 희석에서 약간의 독성이 관찰되었지만 바이러스 검출을 방해하지는 않았다. 특히, 퓨리톤 용액은 hCoV-OC43에 대해 1 시간 및 6 시간 배양한 후 1.7 ~ 2.1 log10 CCID50로 바이러스를 감소하였는바, 효과적인 바이러스 살멸성(virucidal)이 있었다. 양성 대조군과 중화 대조군은 기대한 바와 같았다.Both 70% and 90% diluted Puritone solutions did not interfere with virus detection, although some toxicity was observed at the 1/10 dilution. In particular, the Puritone solution reduced the virus to 1.7 to 2.1 log 10 CCID50 after culturing for 1 hour and 6 hours against hCoV-OC43, showing effective virucidal activity. The positive and neutralizing controls were as expected.
a mL 당 바이러스의 Log10 CCID50, 평균 3 회 복제 ± 표준 편차b LRV (로그 감소 값)는 바이러스 대조군과 비교하여 바이러스 감소이다. a Log 10 CCID50 of virus per mL, mean of three replicates ± standard deviation b LRV (log reduction value) is the reduction of virus compared to virus control.
*** P <0.001 (단방향 ANOVA 및 Dunnett 사후 테스트에 의해 처리되지 않은 바이러스 대조군 (물)과 비교). 통계 분석을 위해 "<"기호는 무시되었다. *** P < 0.001 (compared with untreated virus control (water) by one-way ANOVA and Dunnett's post hoc test). For statistical analysis, the “<” symbol was ignored.
실시예Example 2: SARS- 2: SARS- CoVCoV -2에 대한 -2 for 퓨리톤의puriton's 살바이러스killing virus 효과 effect
상기 표 1과 같은 조성의 퓨리톤이 SARS-CoV-2 (COVID-19) 미치는 영향을 확인하기 위하여 유타주립대학교 (Utah State University)의 항바이러스 연구소(Institute for Antiviral Research)에 의뢰하여 하기와 같은 방법으로 실험하였다.In order to confirm the effect of puritone of the composition shown in Table 1 above on SARS-CoV-2 (COVID-19), we requested the Institute for Antiviral Research at Utah State University to conduct the following The experiment was conducted using this method.
구체적으로, SARS-CoV-2 (COVID-19) 스톡은 2% FBS 및 50 μg/mL 젠타마이신이 포함된 MEM 배지를 사용하여 Vero 76 세포에서 바이러스를 성장시켜 준비하였다.Specifically, SARS-CoV-2 (COVID-19) stocks were prepared by growing the virus in Vero 76 cells using MEM medium containing 2% FBS and 50 μg/mL gentamicin.
상기 퓨리톤 용액을 90 % 및 70 %의 농도로 희석한 후 이를 3중 튜브에 넣은 후 상기 준비된 바이러스 스톡을 첨가하였다. 독성(toxicity) 및 중화(neutralization) 대조군으로 사용하기 위해 각 준비된 농도의 하나의 튜브에만 상기 바이러스 스톡을 첨가하였다. 에탄올 (50%)은 양성 대조군으로 실험하였으며, 음성 대조군으로 물만을 사용하였다.The puriton solution was diluted to a concentration of 90% and 70%, placed in a triple tube, and then the prepared virus stock was added. The virus stock was added to only one tube at each prepared concentration to be used as a toxicity and neutralization control. Ethanol (50%) was used as a positive control, and only water was used as a negative control.
바이러스 스톡이 첨가된 시료들을 실온에서 1 시간동안 배양하였다. 그 다음 각 시료를 5 % FBS 및 50 μg/mL 젠타마이신이 함유된 MEM 배지에서 1/10로 희석하여 중화시켰다. 중화된 시료는 시험 배지에서 8 로그 희석을 사용하여 연속 희석하였다. 각 희석액을 80-100 % 컨플루언트 Vero 76 세포가 있는 96-웰 플레이트의 4개 웰에 첨가하였다. 독성 대조군을 추가적인 3개의 웰에 추가하고 바이러스 (50 CCID50)로 감염시켜 중화 대조군으로 사용하였으며, 플레이트된(plated) 역가 분석(titer assay)에서 잔류 시료가 생존 바이러스의 성장 및 검출을 억제하지 않도록 하였다. 모든 플레이트는 37 ± 2℃, 5 % CO2에서 배양하였다.Samples containing virus stock were incubated at room temperature for 1 hour. Each sample was then neutralized by diluting 1/10 in MEM medium containing 5% FBS and 50 μg/mL gentamicin. Neutralized samples were serially diluted in test medium using 8 log dilutions. Each dilution was added to four wells of a 96-well plate with 80-100% confluent Vero 76 cells. A virulence control was added to three additional wells and infected with virus (50 CCID50) to serve as a neutralization control, ensuring that residual samples did not inhibit the growth and detection of viable virus in the plated titer assay. . All plates were cultured at 37 ± 2°C and 5% CO 2 .
On day 5 post-infection plates were scored for presence or absence of viral cytopathic effect (CPE). The Reed-Muench method was used to determine end-point titers (50% cell culture infectious dose, CCID50) of the samples, and the log reduction value (LRV) of the compound compared to the negative (water) control was calculated.On day 5 post-infection plates were scored for presence or absence of viral cytopathic effect (CPE). The Reed-Muench method was used to determine end-point titers (50% cell culture infectious dose, CCID50) of the samples, and the log reduction value (LRV) of the compound compared to the negative (water) control was calculated.
감염 후 5일째에 플레이트는 CPE(viral cytopathic effect)의 존재 또는 부재에 대해 점수를 매겼다. Reed-Muench 방법을 사용하여 샘플의 종점 역가 (50 % 세포 배양 감염 용량, CCID50)를 결정하였고 음성(물) 대조군과 비교한 화합물의 로그 감소값 (Log Reduction Value; LOR)을 계산하였다. 그 결과를 하기 표 3 및 도 2와 3에 나타내었다.At day 5 post infection, plates were scored for the presence or absence of viral cytopathic effect (CPE). The endpoint titer (50% cell culture infectious dose, CCID50) of the samples was determined using the Reed-Muench method and the log reduction value (LOR) of the compound compared to the negative (water) control was calculated. The results are shown in Table 3 and Figures 2 and 3 below.
a mL 당 바이러스의 Log10 CCID50, 평균 3 회 복제 ± 표준 편차b LRV (로그 감소 값)는 바이러스 대조군과 비교하여 바이러스 감소이다. a Log 10 CCID50 of virus per mL, mean of three replicates ± standard deviation b LRV (log reduction value) is the reduction of virus compared to virus control.
상기 표 2 및 도 2와 3에서 볼 수 있는 바와 같이, 대조군의 바이러스는 0.1 mL 당 3.5 log10 CCID50이었습니다. Puriton은 SARS-CoV-2 (COVID-19)와 함께 1 시간 배양한 후 바이러스를 > 2.8 log10 CCID50 (> 99.8 %)로 감소 시켰다. 양성 대조군과 중화 대조군은 기대한 바와 같았다.As can be seen in Table 2 above and Figures 2 and 3, the virus in the control group was 3.5 log 10 CCID50 per 0.1 mL. Puriton reduced the virus to >2.8 log 10 CCID50 (>99.8%) after 1 hour incubation with SARS-CoV-2 (COVID-19). The positive and neutralizing controls were as expected.
Claims (4)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020200169727A KR102603469B1 (en) | 2020-12-07 | 2020-12-07 | COVID-19 Virucidal composition comprising PURITON and uses thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020200169727A KR102603469B1 (en) | 2020-12-07 | 2020-12-07 | COVID-19 Virucidal composition comprising PURITON and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20220080524A KR20220080524A (en) | 2022-06-14 |
| KR102603469B1 true KR102603469B1 (en) | 2023-11-17 |
Family
ID=81980274
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020200169727A KR102603469B1 (en) | 2020-12-07 | 2020-12-07 | COVID-19 Virucidal composition comprising PURITON and uses thereof |
Country Status (1)
| Country | Link |
|---|---|
| KR (1) | KR102603469B1 (en) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101973198B1 (en) | 2018-01-16 | 2019-04-26 | (주)카데시인코퍼레이션 | Composition for preventing and treating asthmatic disease comprising mineral ion complex |
| KR102037431B1 (en) * | 2018-11-30 | 2019-10-28 | (주)카데시인코퍼레이션 | An antibacterial composition comprising plant extracts and the antiviral agent comprising the same |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102101215B1 (en) * | 2018-02-09 | 2020-04-17 | 정영환 | Deodorant composition for spraying and method for producing the same |
-
2020
- 2020-12-07 KR KR1020200169727A patent/KR102603469B1/en active IP Right Grant
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101973198B1 (en) | 2018-01-16 | 2019-04-26 | (주)카데시인코퍼레이션 | Composition for preventing and treating asthmatic disease comprising mineral ion complex |
| KR102037431B1 (en) * | 2018-11-30 | 2019-10-28 | (주)카데시인코퍼레이션 | An antibacterial composition comprising plant extracts and the antiviral agent comprising the same |
Also Published As
| Publication number | Publication date |
|---|---|
| KR20220080524A (en) | 2022-06-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5092145B2 (en) | Anti-norovirus agent and composition containing the same | |
| JP5421901B2 (en) | Antiviral agent and antiviral composition against non-enveloped viruses of the genus Enterovirus | |
| KR101796423B1 (en) | Composition and ladies genital area cleanser composition comprising composition for inducing Antiviral and antibacterial cause vaginitis and method for manufacturing the same | |
| JP6164621B2 (en) | Hydrogen-containing antimicrobial agent | |
| KR20160079473A (en) | Preparation method of cleaning or disinfecting composition having antiviral activity by containing green tea extract as active component | |
| JP2016530222A (en) | Nanoparticulate titanium dioxide nanomaterials modified with functional groups and citrus extract adsorbed on the surface for the removal of a wide range of microorganisms | |
| CN104336078A (en) | Chlorine-containing Chinese herbal medicine air disinfectant, and preparation method and application thereof | |
| US20160151436A1 (en) | Treatment of Herpes, Pseudomonas, Staph, and Hepatitis | |
| KR102603469B1 (en) | COVID-19 Virucidal composition comprising PURITON and uses thereof | |
| CN105012581A (en) | Fresh aloe antibacterial composite, application and preparing method of fresh aloe antibacterial composite | |
| KR20030019097A (en) | Compositions for treatment and prevention of cold having antiviral activity | |
| KR20160079459A (en) | Cleaning or disinfecting composition having antiviral activity by containing green tea extract as active component | |
| JP5117644B2 (en) | Preventive agent against influenza virus infection | |
| US11298393B2 (en) | Composition comprising a mixture of an extract and bentonite | |
| CN117957006A (en) | Compositions and methods for treating diseases using fractionated honey | |
| KR102252009B1 (en) | Antiviral or antibacterial composition containing extracts of Torreya nucifera leaf | |
| CN111450298A (en) | Marine brown algae oligosaccharide herbal atomizing agent and preparation method thereof | |
| US11666621B2 (en) | Composition having inhibitory effect on virus and bacteria | |
| KR102110663B1 (en) | Process for Compositions of Disinfectants for Viruses of Porcine Epidemic Diarrhea & Porcine Reproductive and Respiratory Syndrome Including Extract of Pleurotus nebrodensis | |
| CN111450297A (en) | Marine fucoidin herbal atomizing agent and preparation method thereof | |
| CN113350487A (en) | Antiviral composition and preparation method and application thereof | |
| JP2004002361A (en) | Anti-influenza virus agent | |
| JP3563327B2 (en) | Antibacterial and preservatives | |
| JP2004345971A (en) | Anti-influenza virus agent using chlorogenate derivative | |
| KR102344582B1 (en) | Composition for antiviral comprising natural extracts |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| E902 | Notification of reason for refusal | ||
| E902 | Notification of reason for refusal | ||
| E701 | Decision to grant or registration of patent right | ||
| GRNT | Written decision to grant |